2023
DOI: 10.1128/spectrum.01793-23
|View full text |Cite
|
Sign up to set email alerts
|

Salivary antibodies induced by BA.4/BA.5-convalescence or bivalent booster Immunoglobulin vaccination protect against novel SARS-COV-2 variants of concern

Abstract: Currently, SARS-CoV-2 Omicron BA.5 subvariants BF.7 and BQ.1.1 are rapidly emerging worldwide. To evaluate the SARS-CoV-2-neutralizing capacity of sera and saliva from triple vaccinated individuals, either boosted with an adapted bivalent COVID-19 vaccine or recovered from BA.4/BA.5 infection, we analyzed the sensitivity of replication-competent SARS-CoV-2 Omicron subvariants BA.4/5, BQ.1.1 and BF.7 to neutralization. Analysis of SARS-CoV-2-specific IgGs and IgAs showed increased serum IgG titers in the vaccin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 35 publications
0
1
0
Order By: Relevance
“…While LDH and IL-6 expression were significantly higher in BA.5 compared to BQ1.1 and BF.7, viral loads and TEER were only slightly changed. In a previous study, we also demonstrated elevated viral loads in BA.5-infected HAE cultures compared to BF.7-or BQ1.1-infected tissue models (22). So far, human cohort studies investigated disease severity between Delta and Omicron waves, but only little is known about the pathogenicity between Omicron subvariants (23).…”
Section: Discussionmentioning
confidence: 80%
“…While LDH and IL-6 expression were significantly higher in BA.5 compared to BQ1.1 and BF.7, viral loads and TEER were only slightly changed. In a previous study, we also demonstrated elevated viral loads in BA.5-infected HAE cultures compared to BF.7-or BQ1.1-infected tissue models (22). So far, human cohort studies investigated disease severity between Delta and Omicron waves, but only little is known about the pathogenicity between Omicron subvariants (23).…”
Section: Discussionmentioning
confidence: 80%